Status:
COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma
Lead Sponsor:
Klinikum Bayreuth GmbH
Collaborating Sponsors:
Peking University Cancer Hospital & Institute
Sana Klinikum Hof
Conditions:
NSCLC
Eligibility:
All Genders
18+ years
Brief Summary
Retrospective study in patients with therapy-naive non small cell lung carcinoma correlating presurgical F18-FDG-PET/CT imaging texture analysis data with postsurgical molecular pathology data and cli...
Detailed Description
Section 1:title and overview Title: Relationship between histopathological features, mutation status, 18F-FDG PET/CT radiomic imaging parameters as well as clinical outcome in patients with treatment-...
Eligibility Criteria
Inclusion
- Retrospective selection of both German cohort NSCLC patients with concomitant gene mutation results, CTCs accounting results and 18F-FDG PET/CT imaging data before lung tumor surgery (both German patient cohorts)
- Retrsopective selection of Chinese NSCLC patients with concomitant gene mutation results, CTCs accounting results and 18F-FDG PET/CT imaging data before lung tumor surgery (Chinese patient collective)
Exclusion
- NSCLC patients with surgical resection of the target/primary tumor before 18F-FDG PET/CT scanning.
- NSCLC patients with elevated blood glucose levels (\> 150 mg/dl) immediately before 18F-FDG injection.
- based on PET CT scanning no concomitant malignancies
Key Trial Info
Start Date :
July 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2020
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT04276025
Start Date
July 1 2016
End Date
January 1 2020
Last Update
February 19 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.